Human Growth Hormone vs MGF.

Human growth hormone (hGH, also called somatotropin) is a 191-amino-acid, single-chain polypeptide hormone secreted by somatotroph cells of the anterior pituitary gland. The pharmaceutical form used in medicine and research is recombinant human growth hormone (rhGH, generic name somatropin), an identical 22 kDa sequence manufactured in E. coli or mammalian cells. It is one of the most studied protein hormones, marketed under brands such as Genotropin, Norditropin, Humatrope, Saizen, Nutropin, and Omnitrope.

MGF is a splice variant of insulin-like growth factor 1 (IGF-1), designated IGF-1Ec in humans and IGF-1Eb in rodents, produced locally in skeletal muscle in response to mechanical loading or damage. The synthetic 'MGF' peptide that is sold and studied is the unique C-terminal E-domain (Ec) portion, not the full IGF-1 molecule. It was characterized largely by Geoffrey Goldspink's group, who proposed it as an autocrine and paracrine signal that activates muscle satellite cells. It remains a preclinical research compound with no approved use.

GH binds a single GH receptor (GHR) that dimerizes and signals through the JAK2/STAT5 pathway, driving transcription of target genes including IGF-1. Much of GH's anabolic and growth-promoting action is mediated indirectly by hepatic and local insulin-like growth factor 1 (IGF-1), while GH itself exerts direct effects that are often metabolically opposite to insulin: it stimulates lipolysis, promotes protein accretion, and induces a state of insulin resistance that raises blood glucose. Endogenous secretion is pulsatile, stimulated by hypothalamic GHRH and ghrelin and suppressed by somatostatin, with negative feedback from IGF-1 and GH itself. The net physiologic effects include longitudinal bone growth at open epiphyses, increased lean body mass, reduced fat mass, and altered glucose and lipid handling.

The mechanistic hypothesis is that the MGF E-peptide, generated by a reading-frame shift in IGF-1 splicing after mechanical stress, activates satellite (muscle stem) cells to proliferate through a receptor thought to be distinct from the classical IGF-1 receptor. In this model MGF acts as a local kick-start for repair that precedes the mature IGF-1 which later drives differentiation. This mechanism is characterized in cell and animal models, and even there it is contested. Several independent laboratories have been unable to reproduce a direct proliferative effect of the isolated E-peptide.

The strongest human evidence is for replacement in diagnosed GH deficiency: recombinant somatropin is FDA-approved and supported by randomized trials and systematic reviews (e.g., Health Technology Assessment 2010, PMID 20849734, for pediatric growth disorders) showing improved growth velocity and adult height in children and improved body composition and quality of life in adult GHD (reviewed in Pituitary 2006, PMID 17077947). More recently, a long-acting analog, once-weekly somapacitan, was effective and well tolerated versus placebo and daily GH in adult GHD in a randomized phase 3 trial (J Clin Endocrinol Metab 2020, PMID 32022863). By contrast, evidence for GH in healthy older adults is weak and unfavorable: the landmark Rudman study (N Engl J Med 1990, PMID 2355952) reported body-composition changes in men over 60 but was small and uncontrolled for clinical endpoints, and a systematic review (Liu et al., Ann Intern Med 2007, PMID 17227934) concluded GH produces only small body-composition changes in the healthy elderly while increasing adverse events, and cannot be recommended as anti-aging therapy. Claims of fat loss, muscle gain, or longevity in healthy or athletic populations are not supported by robust controlled human outcome data.

Early work from Goldspink and colleagues in the late 1990s and 2000s reported that mechanically induced IGF-1Ec/MGF expression tracked with muscle hypertrophy and repair, and some cell studies suggested the E-peptide activated satellite cells. The foundational experiments were expression studies rather than treatment studies. Rabbit skeletal muscle subjected to stretch and electrical stimulation showed a shift in IGF-1 splicing toward the alternative variant (PMID 10087355), and rodent muscle subjected to local damage showed the same splicing shift alongside satellite cell activation (PMID 12692175). Those designs establish a correlation between a mechanical stimulus and a transcript, in small animal groups, over short time courses, without blinding and without any peptide being administered. They do not show that giving the isolated E-peptide does anything. That story is directly challenged by Fornaro et al. in the American Journal of Physiology-Endocrinology and Metabolism (2014, PMID 24253050), who found that the MGF E-peptide at concentrations up to 500 ng/mL had no apparent effect on the proliferation of C2C12 myoblasts or primary human muscle stem cells, whereas mature IGF-1 did. That paper tested synthetic E-peptide obtained from more than one source and included the positive control that much of the earlier literature lacked, which is why it carries substantial weight against the original claim. The contrast with better-characterized molecules in the same family is stark. Mature IGF-1 has decades of receptor pharmacology behind it, and its recombinant form mecasermin is an approved drug for severe primary IGF-1 deficiency, with defined pharmacokinetics, a known hypoglycemia risk, and labeled monitoring requirements. MGF has none of that. There are essentially no controlled human trials of synthetic MGF for muscle growth or repair, no human pharmacokinetic data, no confirmed receptor, no toxicology package, and no outcome data of any kind. The evidence base is preclinical, mixed, and negative in key experiments.

Documented adverse effects, drawn largely from the healthy-elderly trials and GHD populations, include fluid retention and edema, arthralgias and joint swelling, carpal tunnel syndrome, and impaired glucose tolerance or new-onset diabetes due to GH-induced insulin resistance (Liu 2007, PMID 17227934). Acromegaly-like features and gigantism follow chronic GH excess. Long-term safety signals exist: the French SAGhE analysis and related cohorts raised concern about excess circulatory/cerebrovascular mortality after childhood GH treatment, prompting an FDA safety review, though the larger pooled SAGhE cohort (Lancet Diabetes Endocrinol 2020) provided more reassuring overall mortality data; the question of long-term cardiovascular and neoplastic risk remains incompletely resolved. GH is contraindicated in active malignancy, acute critical illness, and proliferative diabetic retinopathy. Non-prescription "GH" products and gray-market vials carry additional risks of misidentification, contamination, and incorrect labeling that are not characterized in any controlled study.

There is no meaningful human safety data for injected synthetic MGF. No clinical trial has been conducted, so there is no reported adverse-event profile, no established tolerated exposure, no immunogenicity assessment, and no chronic toxicology. Theoretical concerns follow from IGF-1 biology, including unregulated growth-factor signaling and the possibility of promoting proliferation of pre-existing tumor cells, although the isolated E-peptide's own activity is uncertain. That uncertainty cuts both ways. A peptide that does not measurably act on muscle stem cells in culture is unlikely to carry the full risk profile of mature IGF-1, but it is also not established to be inert, and the receptor it supposedly acts through has never been identified, which makes off-target prediction impossible. Injected peptides carry generic risks independent of the sequence, including local reactions, sterile abscess, infection from non-sterile preparation, and antibody formation against a foreign or modified sequence. Pegylated versions sold as PEG-MGF add a further unknown, since polyethylene glycol conjugates raise tissue-accumulation and anti-PEG antibody questions that have not been examined for this molecule at all. Material sold online as MGF or PEG-MGF is unregulated and of unverified identity and purity, and independent testing of the grey peptide market has repeatedly found mislabeled contents, under-filled vials, and bacterial contamination. Any legitimate study would require sterility and endotoxin testing of the material, immunogenicity monitoring, measurement of the IGF-1 axis, and exclusion of participants with a cancer history before first exposure. Human safety is uncharacterized.

Recombinant somatropin is FDA-approved (first approved 1985–1987) for specific indications including pediatric GH deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature, idiopathic short stature, chronic renal insufficiency, adult GH deficiency, and HIV-associated wasting; non-approved uses such as anti-aging, bodybuilding, or athletic enhancement are off-label and, in the US, distribution for such uses is specifically restricted by law. GH is a prohibited substance in and out of competition under the World Anti-Doping Agency (WADA) code.

MGF is not approved by the FDA or any regulator and holds no marketing authorization for any indication. It is sold only as a research chemical. Growth-factor peptides of this type are prohibited in sport by WADA.